Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 11INDUSTRY 6NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Smoking Cessation 1Cancer Survivor 1

Interventions

Cyclophosphamide 178Radiotherapy 147Paclitaxel 128Carboplatin 124Bevacizumab 123Cisplatin 119Doxorubicin 111Fluorouracil 107Etoposide 102Filgrastim 99Vincristine 88Leucovorin 82Bortezomib 80Gemcitabine 76aldesleukin 74Sorafenib 70Cytarabine 70Taxes 69fludarabine phosphate 67Irinotecan 66Docetaxel 64Oxaliplatin 60sargramostim 58Sirolimus 58temsirolimus 56Erlotinib Hydrochloride 56Methotrexate 55Rituximab 54Vorinostat 52Radiation 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NIH × Bupropion × Clear all
NCT00322205 2017-01-11

Bio-behavioral Lung Cancer Prevention Program

National Institute on Drug Abuse (NIDA)

Phase 4 Completed
555 enrolled

Smoking Cessation

NCT00079469 2012-03-08

Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke

National Institutes of Health Clinical Center (CC)

Phase NA Completed
Other solid neoplasm

Cancer Survivor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡